Background: Obstructive sleep apnea (OSA) has been linked to tumorigenesis and tumor progression. Objectives: The Sleep Apnea in Lung Cancer (SAIL) study (NCT02764866) was designed to determine the prevalence of OSA in patients with lung cancer. Methods: Cross-sectional study including consecutive patients with newly diagnosed lung cancer. All patients were offered home sleep apnea testing (HSAT) and administered a sleep-specific questionnaire prior to initiating oncologic treatment. Sleep study-related variables, symptoms, and epidemiologic data as well as cancer related variables were recorded. Results: Eighty-three patients were enrolled in the SAIL study. Sixty-six completed HSAT. The mean age was 68 ± 11 years and 58% were male with a mean body mass index of 28.1 ± 5.4. Forty-seven percent were current smokers, 42% former smokers, and 11% never smokers with a median tobacco consumption of 51 pack-years. Fifty percent had COPD with a mean FEV1 of 83 ± 22.6% of predicted and a mean DLCO of 85.5 ± 20.1%. Adenocarcinoma was the most common histologic type (46.7%), followed by squamous cell (16.7%) and small cell (16.7%). Most patients were diagnosed at an advanced stage (65% in stages III–IV). The vast majority (80%) had OSA (apnea-hypopnea index [AHI] > 5), and 50% had moderate to severe OSA (AHI > 15) with a mean Epworth Sleepiness Score of 7.43 ± 3.85. Significant nocturnal hypoxemia was common (Median T90: 10.9% interquartile range 2.4–42.2). Conclusions: Sleep apnea and nocturnal hypoxemia are highly prevalent in patients with lung cancer.

Keywords:
Sleep apnea, Lung cancer, Sleep disordered breathing
1.
Garvey JF, Pengo MF, Drakatos P, Kent BD: Epidemiological aspects of obstructive sleep apnea. J Thorac Dis 2015; 7: 920–929.
2.
Gozal D, Farré R, Nieto FJ: Putative links between sleep apnea and cancer: from hypotheses to evolving evidence. Chest 2015; 148: 1140–1147.
3.
Toffoli S, Michiels C: Intermittent hypoxia is a key regulator of cancer cell and endothelial cell interplay in tumours. FEBS J 2008; 275: 2991–3002.
4.
Almendros I, Montserrat JM, Ramirez J, et al: Intermittent hypoxia enhances cancer progression in a mouse model of sleep apnoea. Eur Respir J 2012; 39: 215–216.
5.
Almendros I, Montserrat JM, Torres M, et al: Intermittent hypoxia increase melanoma metastasis to the lung in a mouse model of sleep apnea. Respir Physiol Neurobiol 2013; 186: 303–307.
6.
Campos-Rodriguez F, Martinez-Garcia MA, Martinez M, et al: Association between obstructive sleep apnea and cancer incidence in a large multicenter Spanish cohort. Am J Respir Crit Care Med 2013; 187: 99–106.
7.
Nieto FJ, Peppard P, Young T, Finn L, Hla KM, Farré R: Sleep disordered breathing and cancer mortality: results from the Wisconsin Sleep Cohort Study. Am J Respir Crit Care Med 2012; 186: 190–194.
8.
Martinez-Garcia MA, Campos-Rodriguez F, Duran-Cantolla J, et al: Association between nocturnal hypoxemia and cancer mortality. Longitudinal multicenter study in 5,467 patients from the Spanish Cohort. Eur Respir J 2012; 40(suppl 56): 709.
9.
Martínez-García MA, Martorell-Calatayud A, Nagore E, et al: Association between sleep disordered breathing and aggressiveness markers of malignant cutaneous melanoma. Eur Respir J 2014; 43: 1661–1668.
10.
Rami-Porta R, Ball D, Crowley J, Giroux DJ, et al: The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007; 2: 593–602.
11.
Berry RB, Budhiraja R, Gottlieb DJ, et al: American Academy of Sleep Medicine. Rules for scoring respiratory events in sleep: update of the 2007 AASM manual for the scoring of sleep and associated events. Deliberations of the sleep apnea definitions task force of the American academy of sleep medicine. J Clin Sleep Med 2012; 8: 597–619.
12.
Franklin KA, Lindberg E: Obstructive sleep apnea is a common disorder in the population-a review on the epidemiology of sleep apnea. J Thorac Dis 2015; 7: 1311–1322.
13.
Heinzer R, Vats S, Marques-Videl P, et al: Prevalence of sleep-disordred breathing in the general population: the Hypnolaus study. Lancet Resp Med 2015; 3: 310–318.
14.
Weitzenblum E, Chaouat A, Kessler R, Canuet M: Overlap syndrome: obstructive sleep apnea in patients with chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5: 237–241.
15.
Kendzerska T, Leung RS, Hawker G, Tomlinson G, Gershon AS: Obstructive sleep apnea and the prevalence and incidence of cancer. CMAJ 2014; 186: 985–992.
16.
Gozal D, Ham SA, Mokhlesi B: Sleep apnea and cancer: analysis of a nationwide population sample. Sleep 2016; 39: 1493–1500.
17.
Dreher M, Krüger S, Schulze-Olden S, Keszei A, Storre JH, Woehrle H, Arzt M, Müller T: Sleep-disordered breathing in patients with newly diagnosed lung cancer. BMC Pulm Med 2018; 18: 72.
18.
Li L, Lu J, Xue W, Wang L, Zhai Y, Fan Z, Wu G, Fan F, Li J, Zhang C, Zhang Y, Zhao J: Target of obstructive sleep apnea syndrome merge lung cancer: based on big data platform. Oncotarget 2017; 8: 21567–21578.
19.
Costa LE, Uchôa CH, Harmon RR, Bortolotto LA, Lorenzi-Filho G, Drager LF: Potential underdiagnosis of obstructive sleep apnoea in the cardiology outpatient setting. Heart 2015; 101: 1288–1292.
20.
Martínez-García MA, Campos-Rodriguez F, Durán-Cantolla J, et al: Obstructive sleep apnea is associated with cancer mortality in younger patients. Sleep Med 2014; 15: 742–748.
21.
Almendros I, Montserrat JM, Ramírez J, et al: Intermittent hypoxia enhances cancer progression in a mouse model of sleep apnoea. Eur Respir J 2012; 39: 215–217.
22.
Almendros I, Montserrat JM, Torres M, et al: Intermittent hypoxia increases melanoma metastasis to the lung in a mouse model of sleep apnea. Respir Physiol Neurobiol 2013; 186: 303–307.
23.
Bishop JN, Bataille V, Gavin A, et al: The prevention, diagnosis, referral and management of melanoma of the skin: concise guidelines. Clin Med (Lond) 2007; 7: 283–290.
24.
Khalid U, Spiro A, Baldwin C, et al: Symptoms and weight loss in patients with gastrointestinal and lung cancer at presentation. Support Care Cancer 2007; 15: 39–46.
25.
Ross PJ, Ashley S, Norton A, et al: Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer 2004; 90: 1905–1911.
26.
Cowan DC, Livingston E: Obstructive Sleep Apnoea Syndrome and Weight Loss: review. Sleep Disord 2012; 2012: 163296.
27.
de Torres JP, Marín JM, Casanova C, Cote C, Carrizo S, Cordoba-Lanus E, Baz-Dávila R, Zulueta JJ, Aguirre-Jaime A, Saetta M, Cosio MG, Celli BR: Lung cancer in patients with chronic obstructive pulmonary disease – incidence and predicting factors. Am J Respir Crit Care Med 2011; 184: 913–919.
28.
Parrón D, Pazos M, Rodriguez P, Gotera C, Mahíllo-Fernández I, Peces-Barba G, Seijo LM: COPD is commonly underdiagnosed in patients with lung cancer: results from the RECOIL study (retrospective study of COPD infradiagnosis in lung cancer). Int J Chron Obstruct Pulmon Dis 2017; 12: 1033–1038.
29.
Gharib SA, Seiger AN, Hayes AL, Mehra R, Patel SR: Treatment of obstructive sleep apnea alters cancer-associated transcriptional signatures in circulating leukocytes. Sleep 2014; 37: 709–714.
30.
Corral J, Sánchez-Quiroga MÁ, Carmona-Bernal C, et al: Spanish Sleep Network. Conventional polysomnography is not necessary for the management of most patients with suspected obstructive sleep apnea. Am J Respir Crit Care Med 2017; 196: 1181–1190.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.